Bovine Respiratory Disease Complex Study Guide

Overview and Clinical Importance

Bovine Respiratory Disease Complex (BRDC), also known as "shipping fever" or "undifferentiated fever," represents the most economically significant disease affecting the North American beef cattle industry. This multifactorial syndrome results from complex interactions between environmental stressors, host immune status, viral pathogens, and bacterial agents. The disease is characterized by cranioventral bronchopneumonia and typically develops when stress-induced immunosuppression allows commensal upper respiratory bacteria to colonize the lower respiratory tract. Understanding the pathogenesis, key pathogens, clinical presentation, and treatment principles is essential for both clinical practice and NAVLE success.

BRDC Pathogenesis: The Disease Triangle

BRDC development requires the convergence of three key factors: host susceptibility, environmental stressors, and pathogen exposure. The pathogenesis typically follows a predictable sequence: stress-induced immunosuppression allows viral infection to damage respiratory epithelium and impair mucociliary clearance, creating conditions that permit bacterial colonization of the lower respiratory tract.

Stress Factors and Host Susceptibility

Viral Pathogens of BRDC

Viral agents serve as primary pathogens or predisposing factors that compromise respiratory defenses and facilitate secondary bacterial pneumonia. The major viral pathogens include Bovine Herpesvirus-1 (BoHV-1/IBR), Bovine Respiratory Syncytial Virus (BRSV), Bovine Viral Diarrhea Virus (BVDV), and Parainfluenza-3 Virus (PI-3). This section covers IBR and BRSV in detail.

Infectious Bovine Rhinotracheitis (IBR) - Bovine Herpesvirus-1

Etiology and Epidemiology

Bovine Herpesvirus-1 (BoHV-1) is a double-stranded DNA virus in the family Herpesviridae, subfamily Alphaherpesvirinae. It is highly contagious and causes multiple clinical syndromes including respiratory disease (IBR), genital disease (infectious pustular vulvovaginitis/balanoposthitis), conjunctivitis, and abortion. A critical characteristic of all alphaherpesviruses is the establishment of latent infection in sensory ganglia (trigeminal or sacral), which persists for the life of the animal and can be reactivated during stress.

Clinical Signs

Pathology

Gross lesions in uncomplicated IBR are restricted to the upper respiratory tract. Findings include petechial to ecchymotic hemorrhages on nasal mucosa and paranasal sinuses, foci of necrosis in the nose, pharynx, larynx, and trachea that may coalesce into plaques, and serofibrinous exudate in sinuses. As disease progresses, pseudodiphtheritic membranes may form in the pharynx. Tracheobronchial lymph nodes are swollen and hemorrhagic. Pulmonary lesions indicate secondary bacterial infection rather than primary viral pneumonia.

Diagnosis

Virus Isolation/Detection: Nasal swabs, conjunctival swabs, or tissue samples (from aborted fetuses: liver, lung, adrenal, placenta). PCR provides rapid, sensitive detection. Immunohistochemistry on tissue sections.

Serology: Virus neutralization (VN) or ELISA. Paired samples (acute and convalescent, 3-4 weeks apart) demonstrating greater than or equal to 4-fold titer rise confirm recent infection. gE-deleted marker vaccines allow differentiation of vaccinated from infected animals (DIVA): vaccinated animals are gE-negative/gB-positive; naturally infected animals are gE-positive/gB-positive.

Bovine Respiratory Syncytial Virus (BRSV)

Etiology and Epidemiology

BRSV is a single-stranded, negative-sense RNA virus in the family Pneumoviridae (formerly Paramyxoviridae), genus Orthopneumovirus. It is closely related to human RSV and serves as a valuable comparative model. BRSV is a primary pathogen capable of causing severe lower respiratory disease independently, particularly in calves less than 6 months of age. However, it also predisposes to secondary bacterial pneumonia. The virus has a high mutation rate, creating antigenic variation (subgroups A, B, AB, intermediate). In approximately 90% of BRSV cases, secondary bacterial pneumonia develops, with Pasteurella multocida being the most common secondary invader.

Clinical Signs

Clinical presentation ranges from mild to peracute and fatal. Morbidity is typically high (often greater than 50% of the group), while case fatality ranges from 0-20%. Initial signs include high fever (104-108 degrees F / 40-42 degrees C), depression, anorexia, decreased milk production, and serous nasal discharge. Respiratory signs progress to include hyperpnea, tachypnea (40-100 breaths/min), spontaneous or easily induced cough, and harsh lung sounds on auscultation. A hallmark feature in severe cases is open-mouth breathing and subcutaneous emphysema over the dorsum and withers, resulting from ruptured bullae.

Pathology

Gross lesions include diffuse interstitial pneumonia with subpleural and interstitial emphysema, interstitial edema, and rubbery lung texture (distinguishing it from the firm consolidation of bronchopneumonia). Cranioventral consolidation may be present if secondary bacterial infection has occurred. Histologically, characteristic findings include syncytial cells (multinucleated giant cells) in bronchiolar epithelium and lung parenchyma, intracytoplasmic inclusion bodies, bronchiolar epithelial proliferation/degeneration, alveolar epithelialization, edema, and hyaline membrane formation.

Diagnosis and Treatment

Diagnosis: PCR on nasal swabs, transtracheal wash, or bronchoalveolar lavage. Antigen-capture ELISA on nasal swabs. Serology using paired samples; note that calves with maternal antibodies may not seroconvert despite infection.

Treatment: No specific antiviral therapy exists. Treatment is supportive and aimed at preventing/treating secondary bacterial infection. Broad-spectrum antimicrobials for secondary bacterial pneumonia. NSAIDs (flunixin meglumine 2.2 mg/kg IV) to reduce fever and inflammation–NSAIDs are preferred over corticosteroids due to immunosuppressive effects of the latter. Antihistamines may be considered. Severe cases with hypersensitivity-type reactions require aggressive supportive care.

Bacterial Pathogens of BRDC

The major bacterial pathogens of BRDC are members of the family Pasteurellaceae: Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. Mycoplasma bovis is also increasingly recognized. These organisms are commensal inhabitants of the upper respiratory tract in healthy cattle but become pathogenic when respiratory defenses are compromised. Part 1 focuses on M. haemolytica and P. multocida.

Mannheimia haemolytica

Etiology and Virulence Factors

Mannheimia haemolytica (formerly Pasteurella haemolytica) is considered the most important bacterial pathogen of BRDC and is most frequently isolated from pneumonic lungs. It is a gram-negative coccobacillus that produces beta-hemolysis on blood agar. Serotype A1 is most commonly associated with bovine pneumonia. Key virulence factors include:

• Leukotoxin (LktA): RTX toxin that lyses bovine leukocytes and platelets; major virulence factor responsible for tissue destruction and fibrin deposition
• Lipopolysaccharide (LPS/Endotoxin): Triggers inflammatory cascade, fever, septic shock
• Capsular Polysaccharide: Inhibits phagocytosis and complement-mediated killing
• Adhesins and Fimbriae: Facilitate colonization of respiratory epithelium
• Iron-acquisition Proteins: Enable survival in iron-limited host environment

Clinical Signs and Pathology

M. haemolytica causes acute fibrinous (lobar) bronchopneumonia characterized by severe, rapidly progressive disease. Clinical signs include high fever (104-107 degrees F), depression, anorexia, mucopurulent nasal discharge, cough, and marked dyspnea. Auscultation reveals harsh lung sounds, crackles, and absence of sounds in consolidated areas.

Gross Pathology: Bilateral, cranioventral consolidation with characteristic "marbled" appearance due to alternating pale areas of coagulation necrosis and dark red areas of acute inflammation. Interlobular septa are distended with fibrin-rich edema. Fibrinous pleuritis is common (pleuropneumonia). Cut surface reveals firm, hepatized lung with fibrinosuppurative exudate in airways.

Pasteurella multocida

Etiology and Clinical Features

Pasteurella multocida is a gram-negative coccobacillus that is the second most commonly isolated bacterium from BRDC cases. Unlike M. haemolytica, it does not produce a potent leukotoxin and generally causes a less severe, more chronic suppurative bronchopneumonia. It is frequently involved in enzootic calf pneumonia in dairy calves and may be the predominant secondary bacterial invader following BRSV infection.

Gross Pathology: Bilateral, cranioventral suppurative bronchopneumonia with lobular distribution. Affected lobes are consolidated, varying from pink-gray to dark red or gray. Pleuritis is usually absent or minimal. Cut surface shows bronchiole-centered lesions with purulent exudate. The pneumonia tends to be less fulminant than M. haemolytica and may become chronic with abscessation.

Comparison of Major Bacterial Pathogens

Clinical Assessment and Diagnosis

Clinical Scoring Systems

Early detection is critical for successful BRDC treatment. Several clinical scoring systems have been developed to standardize disease identification. The DART system (Depression, Appetite, Respiration, Temperature) is commonly used in feedlot settings. The Wisconsin Calf Scoring System evaluates nasal discharge, ocular discharge, ear position/head tilt, cough, and rectal temperature for pre-weaned dairy calves.

Exam Focus: Clinical scoring has limitations–cattle are prey animals that mask illness, and BRD has low sensitivity for clinical detection (approximately 62%). Subclinical BRD is common. Thoracic ultrasound can detect lung consolidation in calves without obvious clinical signs.

Treatment of BRDC

Antimicrobial Therapy

Broad-spectrum antimicrobials labeled for BRDC treatment target gram-negative Pasteurellaceae. Early treatment is essential–delayed treatment increases the likelihood of chronic pneumonia, treatment failure, and mortality. Select antimicrobials based on label indications, withdrawal times, and expected pathogen susceptibility.

Supportive Care

• NSAIDs: Flunixin meglumine (2.2 mg/kg IV) or meloxicam to reduce fever, inflammation, and lung damage
• Fluid Therapy: Oral or IV fluids if dehydrated (1 gallon warm water with electrolytes per 100 lbs body weight)
• Nutrition: Provide high-quality hay; ensure access to fresh water
• Environment: Separate sick animals to hospital pen; ensure good ventilation, reduce dust

Metaphylaxis

Metaphylaxis is the mass treatment of an entire group of high-risk cattle with antimicrobials at the time of arrival to prevent BRD. This approach is economically justified when expected morbidity exceeds 30%. Long-acting macrolides (tulathromycin, tilmicosin, tildipirosin) or florfenicol are commonly used. Metaphylaxis has been shown to substantially decrease morbidity, improve rate of gain, and in some cases decrease mortality.

Memory Aids and Board Tips

BRDC Timeline Memory Aid

"7-21-45" Rule: Peak incidence at 7-21 days post-arrival; highest risk period is first 45 days in feedlot.

BRDC Pathogens Memory Aid: "MPHM + BPBB"

Bacteria: M = Mannheimia haemolytica, P = Pasteurella multocida, H = Histophilus somni, M = Mycoplasma bovis

Viruses: B = BRSV, P = PI-3, B = BVDV, B = BoHV-1 (IBR)

Pathology Pattern Recognition

"Marbled = Mannheimia": Fibrinous bronchopneumonia with marbled appearance (pale necrosis + dark inflammation) = M. haemolytica

"Rubbery + Emphysema = RSV": Interstitial pneumonia with rubbery texture and subcutaneous emphysema = BRSV

"Red Nose + Necrotic Plaques = Rhino": Hyperemic muzzle with white necrotic plaques on nasal septum = IBR

IBR Latency Memory Aid

"Once Infected, Always Infected": BoHV-1 establishes lifelong latency in trigeminal ganglia. Stress reactivates shedding. Purchased seropositive cattle = permanent herd infection risk.